{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-052454","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.330277+00:00","generated_at":"2026-06-13T15:44:51.444702+00:00","sec_items":["5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Allarity Therapeutics implements 1-for-40 reverse stock split to meet Nasdaq minimum bid requirement","bullets":["Reverse stock split effective 4:05 pm NY time June 28, 2023 at a 1-for-40 ratio.","Outstanding shares reduced from 20,142,633 to approximately 503,566; fractional shares rounded up.","Split intended to increase per-share price and bring company into compliance with Nasdaq minimum bid price.","Common stock begins trading on post-split basis under symbol ALLR on June 29, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-052454","json":"https://secwatch.observer/filing/0001213900-23-052454.json","markdown":"https://secwatch.observer/filing/0001213900-23-052454.md","text":"https://secwatch.observer/filing/0001213900-23-052454.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023052454/0001213900-23-052454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023052454/ea180985-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T15:44:51.444702+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f414e7eb0e45a5f9b4c1d24e28993244ae8d7bf","claim":"Allarity Therapeutics, Inc.: Filed Fourth Certificate of Amendment to effect a 1-for-40 reverse stock split of common stock (effective 2023-06-28).","evidence_excerpt":"On June 28, 2023, upon receipt of the required stockholder approval, Allarity Therapeutics, Inc. (the “Company”) filed a Fourth Certificate of Amendment of Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-40 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), effective as of 4:05 p.m. (New York time) on June 28, 2023 (the “Reverse Stock Split”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023052454/0001213900-23-052454-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-06-28"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}